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Abstract
The schizophrenia-associated gene, BRD1, encodes an epigenetic regulator in which chromatin interactome is
enriched with genes implicated in mental health. Alterations in histone modifications and epigenetic regulation
contribute to brain transcriptomic changes in affective disorders and preclinical data supports a role for BRD1 in
psychopathology. However, the implication of BRD1 on affective pathology remains poorly understood. In this study,
we assess affective behaviors and associated neurobiology in Brd1+/− mice along with their responses to Fluoxetine
and Imipramine. This involves behavioral, neurostructural, and neurochemical characterizations along with regional
cerebral gene expression profiling combined with integrative functional genomic analyses. We report behavioral
changes in female Brd1+/− mice with translational value to depressive symptomatology that can be alleviated by the
administration of antidepressant medications. Behavioral changes are accompanied by altered brain morphometry
and imbalances in monoaminergic systems. In accordance, gene expression changes across brain tissues reveal altered
neurotransmitter signaling and cluster in functional pathways associated with depression including ‘Adrenergic-,
GPCR-, cAMP-, and CREB/CREM-signaling’. Integrative gene expression analysis specifically links changes in amygdaloid
intracellular signaling activity to the behavioral treatment response in Brd1+/− mice. Collectively, our study highlights
the importance of BRD1 as a modulator of affective pathology and adds to our understanding of the molecular
mechanisms underlying affective disorders and their treatment response.
Introduction
Psychiatric disorders comprise a heterogeneous group
of disabling conditions collectively characterized by self-
reported and clinically observed changes in state of well-
being and abnormal behaviors1. Suggestive of inter-
connected etiologies, clinical, and therapeutic profiles are
overlapping, and risk factors are shared between dis-
orders2,3. In line with the neurodevelopmental hypothesis
of psychiatric disorders4, this includes a complex interplay
between genetic risks5 and early life adverse exposures6.
However, the molecular and biological mechanisms that
trigger early life programming and development of psy-
chopathology are poorly understood. Epigenetic pro-
cesses, such as acetylation of histone lysine residues, are
linked with brain development as well as lifelong neural
plasticity7 and have been implicated with the pathophy-
siology of both psychotic and affective disorders8.
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Correspondingly, a number of clinically effective anti-
depressants are known to affect the status of cerebral
acetylation of histone lysine residues (Kac)9–11 and his-
tone deacetylases (HDACs) have been suggested as direct
therapeutic targets for depressive disorders12,13. The
interpretation of Kac marks is facilitated by the reader
domains of the bromodomain (BRD) family of proteins14.
Whereas Kac is generally associated with activation of
transcription through opening of the chromatin structure,
they may also signal for the compaction of chromatin,
protein stability, and the regulation of protein-protein
interactions15.
Bromodomain containing-1 (BRD1) has been identified
in complexes involved with both histone acetylation and
chromatin remodeling16,17 and interacts at genomic sites
enriched with genes implicated in neurodevelopmental
processes17,18. BRD1 is widely expressed in human
brain19, differentially regulated in limbic and neocortical
tissues upon exposure to external stressors in rats20,21,
and involved in the epigenetic regulation of embryonic
development, survival, and differentiation of embryonic
stem cells16,22,23. Supporting a role for BRD1 in mental
health, BRD1 has repeatedly been associated with schi-
zophrenia and bipolar disorder in genetic studies24–28,
including gene-wise significant association in the cur-
rently largest schizophrenia GWAS mega-analysis29 and
genome-wide significance in the Psychiatric Genomics
Consortium (PGC1) schizophrenia sample30. The locus
does not show significant association in the most recent
GWASs of bipolar disorder and major depressive dis-
order31,32. Despite being highly intolerant to loss of
function mutations33, a disruptive nonsense mutation in
BRD1 has been reported in a schizophrenia case34. In
concordance, we have recently shown that male mice with
reduced expression of Brd1 (Brd1+/− mice) recapitulate
cardinal features relating to schizophrenia35–38 (Table S1).
In the present study, we assess the impact of reduced Brd1
expression on affective symptomatology, neurochemistry,
and neurobiology in mice along with their responsiveness
to pharmacological intervention using clinically effective
antidepressants. Through global gene expression profiling
of selected brain regions, we assess the neuromolecular
mechanisms that underly BRD1’s role in affective
pathology.
Materials and methods
Animals
A mouse line heterozygous for a targeted deletion
within the Brd1 gene, C57BL/6NTac-Brd1tm1.2Arte/
AborgMmucd (Brd1+/−) was generated by TaconicArte-
mis GmbH (Cologne, Germany) using a targeting vector
(pBrd1 Final cl 1 (UP0257)) with loxP sites flanking exon
3–5 of the Brd1 gene. For further details, see Supple-
mentary Methods and Materials. The mouse strain has
been deposited and is available at Mutant Mouse
Resource and Research Center (MMRRC) at University of
California at Davis (RRID:MMRRC_065563-UCD). All
studies were carried out in accordance with Danish leg-
islation, and permission for the experiments was granted
by the animal welfare committee, appointed by the Danish
Ministry of Food, Agriculture and Fisheries—Danish
Veterinary and Food Administration.
Experimental design
All experiments involved 7–15 mice, 8–11 weeks old, in
each group (figure legends present exact numbers). The
sample size was chosen on the basis of the resource
equation method39. Litter-matched WT and Brd1+/−
mice were randomly allocated to individual tests. Obser-
ver was blind to mice genotypes. General assessment of
neurology, testing in motor coordination tests, prepulse
inhibition (PPI), fear conditioning (FC), 8-arm radial maze
(8ARM), open field (OF), tail suspension test (TST),
forced swim test (FST), bright open field (BOF), light and
dark box (LDB), elevated plus maze (EPM) and quantifi-
cation of neurotransmitters by high-pressure liquid
chromatography (HPLC) were performed in parallel on
age-matched male and female littermates. However, in
this study, PPI, FC, and 8ARM were only reported in
female mice, since corresponding male data have already
been published elsewhere35,36. One batch of mice com-
pleted OF, TST and FST, while another completed BOF,
LDB, and EPM. An independent batch of mice was
injected subcutaneously with either vehicle (normal saline
solution), imipramine (IMN, 1 or 10 mg/kg) or fluoxetine
(FLX, 5 mg/kg), dissolved in saline and subjected to OF,
TST, and FST. Each mouse underwent 2 days of experi-
ments. Day 1: one hour after the injection, the mice
completed TST and were subsequently returned to their
cages. Day 2: mice had a second injection. One hour after
the injection, the mice completed OF and FST. There was
no delay between OF and FST. One hour after the com-
pletion of FST, they were sacrificed, and brains were
collected.
Amphetamine-induced hyperactivity (AIH), cocaine-
induced hyperactivity (CIH), sucrose preference test
(SPT), and 24-h locomotor activity (24HLM) and OF,
TST and FST following administration of antidepressants
were only tested and reported in female mice in this study.
Mice were not reused for other experiments.
General assessment of neurology, motor coordination, and
behavioral tests
Details on functional observation battery, acute pain
response, rotarod, balance beam walking, foot-printing,
FST, TST, SPT, OF, BOF, LDB, EPM, FC, 8ARM, 24HLM,
PPI, AIH, and CIH can be found in Supplementary
Methods and Materials.
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Quantification of neurotransmitters
Mice were sacrificed by cervical dislocation and frontal
cortical, hippocampal, and striatal tissues were collected
by free-hand dissection and processed for quantitative
HPLC analyses of dopamine and serotonin. For details
on HPLC procedures, see Supplementary Methods and
Materials.
Brain morphometry, Golgi-cox staining, and 3-D image
analysis
Left cerebral hemispheres (n= 8/group) were stained
with FD Rapid Golgi-Stain kit (FD Neurotechnologies,
Ellicott City, USA), and cut into 150 µm thick-slices on a
vibratome-3000 (Vibratome, St Louis, MO, USA). Ante-
rior cingulate cortex (aCC) pyramidal neurons were
identified (×60; oil-immersion; numerical-aperture= 1.4)
by their prominent apical dendrites, and 6 neurons/mouse
were chosen by systematic uniform random sampling.
Image stacks (90-105 consecutive images at 1 µm interval)
were captured by optical wide-field microscopy (Olympus
BX50, Tokyo, Japan) and newCAST software (Visio-
pharm, Hoersholm, Denmark). 3-D image reconstruction
and analyses were completed using Imaris software ver-
sion 7.6.3 (Bitplane AG, Zurich, Switzerland). For a
description on brain morphometric analyses, see Supple-
mentary Methods and Materials.
Statistical analysis
STATA 15.1 (StataCorp LLC, College Station, TX) and
GraphPad Prism 8.1.2 (GraphPad Software, San Diego,
CA) software was used for analyzing our data with
appropriate tests of statistical significance including t-test
and two-way RMANOVA. We checked whether all con-
tinuous variables followed Gaussian distribution using
Shapiro–Wilk tests. When the study variables did not
follow Gaussian distribution, appropriate non-parametric
tests such as Mann–Whitney U test were employed.
F tests were used for assessing equality of variances and
Welch corrections were applied, when needed.
RNA-sequencing and data analyses
Mouse brains from IMN (10mg/kg) and FLX (5 mg/kg)
(n= 9–10/group) were sectioned coronally (1 mm thick)
using a slicer matrix (Zivic Instruments, Pittsburgh, USA).
For the IMN (10mg/kg) group, right amygdala (AMG),
striatum, caudate putamen (CPu), and aCC were identi-
fied, and punched by a punch-needle (1 mm diameter) at
−20 °C, whereas for the FLX (5 mg/kg) group only AMG
was sampled. RNA was extracted using Maxwell-16
instrument system and LEV simplyRNA Tissue Kit
(Promega, Madison, USA). Agilent 2100 Bioanalyzer
(Agilent technologies, SantaClara, USA) confirmed the
quality of RNA with a mean RNA Integrity Number (RIN)
of 7.87 (SD 0.26). For AMG samples, libraries were
prepared using TruSeq library preparation kit and RNA-
sequencing performed on the Illumina HiSeq2000 plat-
form (Illumina, San Diego, USA). For CPU and aCC
samples, libraries were prepared using Beijing Genomics
Institute (BGI) library preparation kits and protocols and
sequencing performed on the BGISEQ-500 platform. A
minimum of 10 million clean 50 bp single-end reads were
generated for each sample. Reads that passed quality
control (more than 90% bases having less than 1%
sequencing error; No ambiguous bases) were aligned to
mouse genome (Mus_musculus.GRCm.38.90) by HISAT2
(version 2.1.0)40 and counted by StringTie (version
1.3.4)41. Differentially Expressed Genes (DEGs) were
identified by edgeR3.24.142 and reported after Benjamini-
Hochberg false discovery rate (FDR) (5%) correction (14,
16) or as nominally significant DEGs (p < 0.01). Functional
analyses of all nominally significant DEGs were performed
using Ingenuity Pathway Analysis (Ingenuity, Redwood
City, USA).
Results
General assessment of neurology and motor coordination
Male and female Brd1+/− mice were overall healthy, as
described elsewhere35. However, female mice showed
marginally impaired growth and slightly reduced size35.
Systematic testing of general neurological functions of
female Brd1+/− mice, revealed mildly reduced perfor-
mance in the grip strength and wire-maneuvering tasks
(Table 1). Female Brd1+/−mice did not differ significantly
on their pain response (Fig. S1A), but were mildly
impaired in their motor coordination, as evident from
their rotarod performance (Fig. S1B, two-way ANOVA;
p= 0.047)) and gaiting pattern (Fig. S1F, gaiting uni-
formity, t-test; p= 0.039). However, as they performed
at par with their WT littermates in the beam walking task
(Fig. S1G–H), we considered female Brd1+/− mice fit for
testing in settings assessing complex behaviors. Assess-
ment of motor coordination in male Brd1+/− mice has
been reported previously (Table S1)35.
Locomotor activity and sensorimotor response in Brd1+/−
mice
General locomotor activity was assessed in the OF
where male (Fig. 1a) and female (Fig. 1b) Brd1+/− mice
performed at par with their WT littermates. As reported
in male Brd1+/− mice (Table S1)35, female Brd1+/− mice
displayed significantly increased acoustic startle respon-
sivity (ASR) (Fig. 1c, two-way ANOVA; p= 0.003), both
when initially introduced to the test setting (Fig. 1c,
Tukey’s post hoc test; p= 0.004) and before baseline PPI
testing (Fig. 1c, Tukey’s post hoc test; p= 0.006).
Response latency to the startle was furthermore sig-
nificantly shorter in female Brd1+/− mice than in WT
mice (Fig. 1d, t-test; p= 0.044). The magnitude of baseline
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startle is known to influence PPI43. Accordingly, female
Brd1+/− mice displayed reduced PPI across the span of
tested prepulse intensities (Fig. 1e, two-way ANOVA;
p= 0.049).
Cognition
Female Brd1+/− mice froze significantly less than WT
mice during the conditioning phase of FCS (Fig. 1f, two-
way ANOVA; p= 0.002) and when returning to the same
Table 1 Basic neurological functioning and behaviors in female Brd1+/− mice.
Test Parameters Outcome Implication
Irwin’s observational battery Undisturbed behavior — Basic neurological functioning
Finger approach — Basic neurological functioning
Touch escape — Basic neurological functioning
Grip strength ↓ Basic neurological functioning
Visual placing response — Basic neurological functioning
Corneal response — Basic neurological functioning
Toe-pinch response — Basic neurological functioning
Wire-maneuver ↓ Basic neurological functioning
Limb- and abdominal tone — Basic neurological functioning
Tail-pinch response — Basic neurological functioning
Hot-plate Response — Acute pain response
Beam walking Crossing speed/missteps — Motor coordination
Rota-rod Latency to fall ↓ Motor coordination
Foot-printing test Stride length — Motor coordination
Base width — Motor coordination
Step uniformity ↓ Motor coordination
Fear Conditioning (FCS) Conditioning ↓ Conditional learning
Contextual memory (day 2) ↓ Associative memory*
Extinction retrieval — Associative memory
Cue dependent learning — Associative memory
Acoustic startle reactivity (ASR) Startle ↑ Hearing/stress susceptibility
Latency to startle ↓ Stress susceptibility
Prepulse inhibition (PPI) Baseline ↓ Pre-attentive processing
Locomotor activity Novelty-induced — Psycho-motor activity
Amphetamine induced — Meso-limbic drug responsiveness
Cocaine-induced — Meso-limbic drug responsiveness
8 arm radial maze (ARM) Re-entry to baited arms# — Working memory
Entry to non-baited arms# ↑ Non-spatial reference memory
Elevated plus maze (EPM) Time in open arms — Anxiety behavior/Mania
Bright open field (BOF) Time in central zone — Anxiety behavior/Mania
Light and dark box (LDB) Time in light box — Anxiety behavior/Mania
Open field test (OF) Distance moved — Anxiety behavior/Mania
Forced swim test (FST) Immobility ↑ Behavioral despair/Mania
Tail suspension test (TST) Immobility ↑ Behavioral despair/Mania
Sucrose preference test (SPT) Sucrose preference ↓ Anhedonia
#: number of events. *Likely reflect acquisition deficit during conditioning.
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context on the following day (Fig. 1g, t-test; p= 0.03),
collectively suggestive of a central acquisition deficit in
female Brd1+/− mice. However, female Brd1+/− mice did
not differ significantly from the WT mice on their cue
dependent learning (Fig. 1h and Table 1) or on working
memory errors in 8ARM (Fig. 1i). They did, however,
make significantly more entries into the never-baited
arms, indicative of impaired reference memory (Fig. 1j,
two-way ANOVA; p= 0.03) (Table 1). Cognitive perfor-
mance of male Brd1+/− mice tested in parallel has pre-
viously been reported35,36 and results are summarized in
Table S1.
Affective behaviors in Brd1+/− mice
Affective behaviors were assessed in both male and
female Brd1+/− mice (Table 1 and Table S1). Female
Brd1+/− mice did not differ significantly in the time spent
in the central zone of BOF (Fig. 1k), in the light box of
LDB (Fig. 1l) or in the open arms of EPM (Fig. 1m).
Although male Brd1+/− mice spent significantly less time
in the light box of LDB (Fig. 1n, t-test; p= 0.006), they did
not exhibit similar anxiety-like behaviors in BOF (Fig. 1o)
or EPM (Fig. 1p). Suggestive of behavioral despair, female
Brd1+/− mice were significantly more immobile in TST
(Fig. 1q, t-test; p= 0.007) and in FST (Fig. 1r, two-way
ANOVA; p= 0.002) compared to WT mice, whereas this
was not evident in male Brd1+/− mice (Fig. 1s, t). FST
male WT immobility was higher than in female WT mice
(Wilcoxon rank-sum; p= 0.001) and the WT male and
female mice did not differ significantly on their TST
immobility (t-test; p= 0.09)(Fig. 1q–t). Both TST (two-
way ANOVA; p= 0.013) and FST (two-level mixed effects
GLM; p= 0.014) data confirmed statistically significant
interactions between gender and genotypes. Hence, we
decided to assess additional affective behaviors in female
mice only. Circadian rhythm, measured as 24HLM per-
formance, appeared unaltered in female Brd1+/− mice
(Fig. 1u) whereas sucrose preference was significantly
reduced in female Brd1+/− mice compared to WT mice
(Fig. 1v, two-way ANOVA; p= 0.001).
Neurochemistry and psychotropic drug-induced activity
As reported in male Brd1+/− mice (Table S1)35, female
mice displayed unaltered hippocampal serotonin levels
(Fig. 2a) and significantly reduced hippocampal dopamine
levels (Fig. 2b, t-test; p= 0.045) but unaltered fronto-
cortical dopamine levels (Fig. 2c). However, female mice
had significantly less fronto-cortical serotonin (Fig. 2d,
t-test; p= 0.01) and, noticeably, significantly reduced
striatal dopamine (Fig. 2e, t-test; p= 0.02) compared to
WT mice. Further analyses confirmed statistically sig-
nificant interactions between female gender and Brd1+/−
genotype on fronto-cortical serotonin (two-way ANOVA;
p= 0.002) and striatal dopamine (two-way ANOVA; p=
0.002) levels. Additionally, their sensitivity towards the
psychomotor stimulatory effects of amphetamine 5mg/kg
(Fig. 2f) and cocaine 15 or 30mg/kg (Fig. 2g) did not differ
from the sensitivity of WT mice.
(see figure on previous page)
Fig. 1 Behavioral characterization in male and female Brd1+/− mice. a Male mice (Mann–Whitney U= 94.0; p= 0.46). b Female mice (t= 0.20;
p= 0.85): Total distance moved in the open field (OF) (n= 15/group). c Female Brd1+/− mice (n= 18) displayed significantly increased acoustic
startle responsivity (ASR) compared to WT mice (n= 17) (genotype effect, F= 10.10, p= 0.003) both when initially introduced to the test setting
(Tukey’s post hoc test, t= 3.07; p= 0.004) and before baseline PPI testing (Tukey’s post hoc test, t= 2.94; p= 0.006). d Response latency to the startle
was furthermore significantly shorter than in WT mice (t= 2.09, p= 0.044). e Female Brd1+/− mice (n= 18) displayed reduced prepulse inhibition
(PPI) compared to WT mice (n= 17) across the span of tested prepulse intensities (genotype effect, F= 4,163, p= 0.049); Cognitive functioning of
female Brd1+/− mice. f–h Fear conditioning system (FCS) (n= 15/group). f Time spent as freezing during the repeated presentation of conditioning
stimuli (CS; 30 s, 80db, white noise) on day one. Unconditioned stimulus (UCS) was 0.7 mA foot shock for 2 s. Inter-pairing intervals varied with an
average of 60 s (30–120 s). Female Brd1 + /− mice displayed significantly less freezing during the conditioning phase of FCS (F= 12.26; p= 0.002).
g Duration of freezing behavior within the first 3 min, after entering the conditioned context on the second day. Female Brd1+/− mice displayed
significantly reduced freezing behavior (t= 2.23; p= 0.03). h Time spent as freezing during the first presentation of CS (30 s) in the novel context on
the third day. Female Brd1+/−mice did not display cue-dependent learning deficits. i, j 8-Arm Radial Maze (8ARM) (n= 12/group). iWorking memory
errors, measured by the total number of re-entries to baited arms. j Reference memory errors, measured by the total number of entries to non-baited
arms. Our 8ARM setup, which provided clear intramaze cues, predominantly assessed non-spatial memory and associative learning. Female Brd1+/−
mice did not show working memory deficits, but displayed significant non-spatial reference memory deficits (F= 5.57; p= 0.03). k–m Female mice.
k Total time spent in the central zone of bright open field (BOF) (n= 15/group). l Total time spent in the light box of light and dark box test (LDB)
(n= 15/group). m Total time spent in the open arms of elevated plus maze (EPM) (n= 15/group). Female Brd1+/− mice did not display any anxiety
equivalent behaviors. n–p Male mice. n Total time spent in the central zone of BOF (n= 15/group). o Total time spent in the light box of LDB (n=
15/group). This finding was not corroborated by the BOF and EPM results of male Brd1+/−mice. p Total time spent in the open arms of EPM (n= 15/
group). Male Brd1+/− mice spent significantly less time in the light box of LDB (t= 2.97; p= 0.006), but they did not exhibit similar anxiety-like
behaviors in BOF or EPM. q Female Brd1+/− mice were significantly more immobile in TST (n= 15/group; t= 3.01; p= 0.007) (r) and in FST (n= 15/
group; F= 12.26; p= 0.002). s Male Brd1+/− mice did not display such behavioral despair in TST (n= 15/group) (t) and FST (n= 15/group). u Female
Brd1+/− mice did not differ from WT mice in distance moved over 24 h (n= 10/group). Dark indicates the time when the lights were switched off in
the stable, while light indicates the time when they were switched on. v Female Brd1+/− mice showed significantly less sucrose preference than the
WT mice (n= 11/group; F= 14.03; p= 0.001), sucrose preference (weight of 2% sucrose solution consumed/ weight of total fluid consumed) in
percentage. Data shown are mean and SEM for each group *p < 0.05; **p < 0.01.
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Brain volume and neuronal morphology
Total brain volume, as estimated by stereology, was
slightly reduced (~8%) in female Brd1+/− mice (Fig. 2h
and Fig. S1A, t-test; p= 0.041), but with no difference in
brain symmetry (Fig. S2B) or ventricle volume (Fig. S2C,
D). In line with reduced overall brain tissue volume, aCC
pyramidal neurons had significantly shorter dendrites in
female Brd1+/− mice compared to WT mice (Fig. 2i,
t-test; p= 0.008) combined with less dendritic branching
(Fig. 2j, t-test; p= 0.01) and less dendritic spine density
(Fig. 2k, t-test; p < 0.001). 3-D Sholl analysis counting the
dendritic intersections on the concentric spheres with
their centres at soma confirmed that these neurons
had significantly less dendritic branching (Fig. 2l, m,
p < 0.001).
Behavioral response to antidepressants
Provided that the phenomenological and pathophysio-
logical phenotype of female Brd1+/− mice indicate
translational relevance to depressive disorders, they may
be reversible upon the administration of clinically used
antidepressants. In accordance, treatment with Fluoxetine
(FLX) and Imipramine (IMN) reversed the despair-like
behaviors of female Brd1+/− mice, while having negligible
effect on their movements in the OF (Fig. S3). Particularly,
differences in immobility between Brd1+/− and WT mice
during TST, could be reversed by IMN 1 (Fig. 3a) or
10mg/kg (Fig. 3a), and by FLX 5mg/kg (Fig. 3a) with
Brd1+/− mice receiving IMN (Fig. 3b; 1 mg/kg, two-way
ANOVA; p < 0.001 or 10mg/kg, two-way ANOVA; p <
0.001) being significantly less immobile during TST than
the vehicle-treated Brd1+/− mice. Similarly, the differ-
ences in immobility during FST, could be reversed by
IMN 10mg/kg (Fig. 3c) and by FLX 5mg/kg (Fig. 3c),
with IMN (Fig. 3d, two-way ANOVA; p < 0.001) or FLX
(Fig. 3d, two-way ANOVA; p < 0.001) causing reduced
immobility compared to vehicle-treatment. Vehicle-
treated Brd1+/− mice were significantly more immobile
in TST (Fig. 3a, t-test; p < 0.001) and FST (Fig. 3c, t-test;
p= 0.005) than the vehicle-treated WT mice thus
replicating the behavioral despair in untreated female
Brd1+/− mice.
Global gene expression profiling of antidepressant
treatment in Brd1+/− mice
To delineate the molecular signatures accompanying
the behavioral response to antidepressants by Brd1+/−
mice, we conducted global gene expression profiling of
selected brain tissues from mice administered vehicle or
antidepressant (IMN or FLX). Amygdaloid (AMG) tissue
from vehicle administered mice was characterized by
pronounced changes in gene expression involving 144
differentially expressed genes (DEGs) that were significant
after Benjamini–Hochberg false discovery rate (FDR)
correction at 5% (Fig. 4a (mid panel) and Table S2). As
these comprised a high number of predicted/unchar-
acterized genes (Table S2) we subjected nominally sig-
nificant DEGs (p < 0.01, 511 genes) to functional analyses
using ingenuity pathway analysis (IPA) software. This
revealed an overrepresentation of genes acting in biolo-
gical pathways previously implicated with affective beha-
viors, including unfolded protein response44 and α-
adrenergic45-, chemokine46-, G-protein coupled receptor
(GPCR), and Glial cell-derived neurotrophic factor
(GDNF) mediated signaling47 (Fig. 4b and Table S3).
Notably, fold change of implicated DEGs suggested an
activation of G-protein coupled receptor (GPCR) medi-
ated signaling, specifically through the Gaq subunit
associated with, among others, the 5HT2 serotonergic-,
and Alpha-1 adrenergic receptors (Fig. 4b and Table S3).
Supportive of altered amygdaloid intracellular signaling in
Brd1+/− mice, predicted upstream DEG regulators com-
prised a range of stimulus-induced transcription factors,
including FOS, CREB1 and, ADORA2A (Table S4).
Overall, administration of FLX and IMN normalized
the amygdaloid transcriptome in Brd1+/− mice (Fig. 4c),
(see figure on previous page)
Fig. 2 Neurochemistry and psychotomimetic drug sensitivity in female Brd1+/−mice. a–e Neurotransmitter levels were determined by HPLC in
several brain tissues in female Brd1+/− mice in parallel with male Brd1+/− mice as previously reported on ref. 35. a Female mice displayed unaltered
hippocampal serotonin level (n= 9/group). b Significantly reduced hippocampal dopamine level (n= 10/group, t= 2.147, p= 0.045). c Unaltered
fronto-cortical dopamine (n= 9/group). d Less fronto-cortical serotonin (n= 15/group; t= 2.70; p= 0.01) and; e reduced striatal dopamine (n= 10/
group; t= 2.52; p= 0.02) compared to WT mice. 5-HT: 5-hydroxy tryptamine (serotonin); DA: dopamine. f Distance moved before and after
amphetamine 5mg/kg (Amph) injection was similar in female Brd1+/− and WT mice (n= 10/group). g Distance moved before and after cocaine
30 mg/kg injection was similar in female Brd1+/− and WT mice (n= 12/group). h Total brain volume was slightly reduced in female Brd1+/− mice
compared to WT mice (n= 7/group; t= 2.31; p= 0.041). i Total dendritic length including apical and basal dendrites. aCC pyramidal neurons had
significantly shorter dendrites in female Brd1+/−mice compared to WT mice (t= 3.29; p= 0.008). j Mean branch depth: branching depth was defined
by the number of bifurcations from the beginning point to the end of a dendrite. Female Brd1+/− mice had less dendritic branching (t= 3.08; p=
0.01) compared to WT mice. k Mean dendritic spine density (number of spines/ length of dendrites). Female Brd1+/− mice had less dendritic spine
density (t= 9.19; p < 0.001) compared to WT mice. l 3-D Sholl analysis: Number of dendritic intersections on concentric spheres (radius interval
20 µm) with their centres at soma. Neurons in female Brd1+/− mice had significantly less dendritic branching (F= 20.60; p < 0.001) than neurons in
WT mice. m 3-D reconstruction of left: WT neuron and right: Brd1+/− neuron. Data shown are mean and SEM for each group *p < 0.05; **p < 0.01;
***p < 0.001.
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and, convincingly, FLX and IMN administration nearly
completely normalized AMG expression of genes differ-
entially expressed in vehicle administered Brd1+/− mice
(Fig. 4d and Table S6 and S6) without affecting Brd1
expression (Fig. 4a). Whereas the tested dose (10 mg/kg)
of IMN had only minor effect on AMG gene expression
in WT mice, administration of FLX (5 mg/kg) resulted in
massive changes in WT mice (Fig. 4a). Accordingly, we
proceeded with testing only IMN (10 mg/kg) in tissue
samples from aCC and striatum, caudate putamen (CPu).
In aCC, only Brd1 was significantly differentially regu-
lated after FDR correction between Brd1+/− and WT
vehicle groups (Fig. 4e, lower panel) and only 141 genes
were differentially expressed at a nominal significant cut-
off set at 1% (Table S7). This set of genes did not cluster
in distinct biological pathways (Table S8). Like in AMG,
however, administration of antidepressants primarily
affected gene expression in Brd1+/−, and to a lesser
extent, WT mice (Table S9). This included a reduction in
mRNA encoding dopamine receptor 2 (Drd2, Fig. 4e and
Table S9), which was significantly overexpressed in
vehicle administered Brd1+/− mice compared to WT
mice (Fig. 4e and Table S7). In CPu, only Brd1 was sig-
nificantly downregulated after FDR correction in the
vehicle treated group, (Fig. 4f, lower panel and Table S10)
whereas a large number of genes (2260) were differen-
tially expressed at a nominally significant cut-off set at 1%
(Fig. 4f and Table S10). Although CPu and AMG DEGs
generally clustered in the same functional pathways and
involved same predicted upstream transcriptional reg-
ulators (Tables S2, S11, 12), contrary to AMG DEGs, CPu
DEGs consistently reported of inhibited intracellular
signaling initiated by GPCR subunits associated with a
broad range of neurotransmitter receptors (Fig. 4g and
Table S11). Although treatment with IMN overall nor-
malized CPu gene expression between Brd1+/− and WT
mice (Fig. 4f (Top panel)), effects were more pronounced
in WT (Table S13, 1370 nominally significant DEGs)
than in Brd1+/− mice (Table S14, 513 nominally sig-
nificant DEGs) (Fig. 4h).
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Fig. 3 Behavioral response to antidepressant medication in female Brd1+/−mice. a, b Tail suspension test. a Total duration of immobility in the
8 groups (n= 15/group). Comparison between vehicle-treated WT and vehicle-treated Brd1+/− mice confirmed the depression-like behaviors of
female Brd1+/− mice (t= 5.42; p < 0.001). Comparisons between other three pairs indicated that the depressive phenotype of female Brd1+/− mice
could be reversed by antidepressant medications. b Duration of immobility in the four groups of female Brd1+/− mice, which received four different
interventions. Female Brd1+/− mice, that received imipramine 1 (F= 17.55; p < 0.001) and 10 (F= 43.08; p < 0.001) mg/kg, displayed significantly less
depression-like behaviors than the vehicle-treated Brd1+/−mice. c, d Forced swim test. c Total duration of immobility in the 8 groups (n= 15/group).
Comparison between vehicle-treated WT mice and vehicle-treated Brd1+/− mice confirmed the depression-like behaviors of female Brd1+/− mice
(t= 3.14; p= 0.005). Except for 1 mg/kg IMN treated groups, comparisons between other two pairs indicated that the depressive phenotype of
female Brd1+/− mice could be reversed by antidepressant medications. d Duration of immobility in the four groups of female Brd1+/− mice, which
received four different interventions. Female Brd1+/− mice that received imipramine 1 (F= 9.69; p= 0.004) and 10 (F= 35.71; p < 0.001) mg/kg, and
FLX 5 mg/kg (F= 18.05; p < 0.001) displayed significantly less depression-like behaviors than the vehicle-treated Brd1+/− mice. IMN, imipramine; FLX,
fluoxetine. Data shown are mean and SEM for each group. *p < 0.05; **p < 0.01; ***p < 0.001.
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Discussion
Despite the clinical heterogeneity of affective disorders,
their, etiopathologies are partially overlapping and include
an intricate interplay between environmental, genetic, and
epigenetic factors1,8,48–50. Post translational modifications
of histones, such as Kac, have been linked with brain
development7 and particularly the pathophysiology of
affective disorders8,51. Acting as an epigenetic regulator
during neurodevelopment, BRD1 has the potential to
integrate intrinsic and environmental signals into the
shaping of the maturing brain. Here, we demonstrate that
reduced Brd1 expression in female mice results in brain
morphometric alterations accompanied by changes in
behaviors and underlying neurobiology with broad
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translational relevance to affective disorders. Supporting
the predictive validity of female Brd1+/− mice as a model
for depressive pathology, behavioral and molecular
changes in Brd1+/− mice are reversible upon the admin-
istration of clinically effective antidepressants. Finally,
integrative genomic profiling of regional brain tran-
scriptomic effects reveals molecular mechanisms and
tissue specificity associated with affective pathology and
antidepressant treatment effect.
Neuro-implication of reduced Brd1 expression is
sex-biased
Cognitive impairments are common in psychiatric dis-
orders, and although more thoroughly investigated in
male Brd1+/− mice36, both sexes display cognitive
impairments with broad translational relevance, including
central acquisition deficits and impaired reference mem-
ory. Sensorimotor deficits in the form of increased base-
line startle amplitude, which have been reported in a
range of psychiatric disorders52, are similarly seen in both
male and female Brd1+/− mice. However, neither male
nor female Brd1+/− mice display consistent changes in
their risk-taking behaviors. Female Brd1+/− mice, addi-
tionally, did not exhibit marked changes in their circadian
cycle as measured by 24HLM. However, supporting their
translational value as model of depressive symptomatol-
ogy seen in affective disorders53 and the prodromal stage
of schizophrenia54, female Brd1+/− mice displayed
increased immobility during FST and TST indicating
behavioral despair55, and decreased sucrose preference
representing anhedonia56.
Similar to what has been reported in both schizo-
phrenia, bipolar disorder57, and depressed suicide vic-
tims58, female Brd1+/− mice display abnormal brain and
neuronal morphology with reduced dendritic branching
and spine pathology38. Although these parameters have
not been assessed in male Brd1+/− mice, detailed struc-
tural brain imaging followed by stereological estimation of
regional volumes and cell number, have revealed reduced
subcortical volume and striatal cell loss in male Brd1+/−
mice37. Sex differences in animal models of psychiatric
disorders are, however, common and may mirror the
documented sex differences in psychiatric disorders
where symptom profiles and severity differ between
sexes59–64 and where depressive disorders are more pre-
valent among women than men59,63. In line with the
reported divergences in behaviors, the neurochemical
profile of female Brd1+/− mice varied significantly from
what we have previously reported in male Brd1+/−
mice35,36. Unlike male Brd1+/− mice35, female Brd1+/−
mice are not super-sensitive to the psycho-motor stimu-
latory effect of cocaine and PCP. Although both male and
female mice display increased hippocampal dopamine,
only female Brd1+/− mice displayed significantly reduced
levels of cortical serotonin and striatal dopamine, con-
sistent with the monoamine hypothesis of depression65.
Histone modifications act to epigenetically sexually dif-
ferentiate the developing brain and consequently beha-
vior66 by regulating the genomic actions of sex steroid
hormones66,67. Intriguing in this context, BRD1 is a co-
regulator of nuclear hormone receptor-mediated signal-
ing17,18,23 and its chromatin interactome enriched with
estrogen and androgen target genes17.
Neuro-molecular effect of reduced Brd1 expression reflect
brain regional changes in intracellular signaling activity
Using transcriptomic profiling to broadly capture Brd1-
mediated neuro-molecular changes across multiple brain
(see figure on previous page)
Fig. 4 Cerebral gene expression profiling of cortical and subcortical brain tissues in vehicle and antidepressant administered female
Brd1+/−mice. a Gene expression profile in AMG tissue from vehicle, IMN and FLX administered female WT (n= 8/group) and Brd1+/− (n= 8/group)
mice. Gray, red, and blue color mark genes that are nominally significantly differentially expressed, significantly upregulated after FDR correction, and
significantly downregulated after FDR correction between Brd1+/− and WT mice, respectively. b Functional genomic analysis using ingenuity
pathway analysis IPA software identifies pathways that are enriched with nominally significantly AMG DEGs and predicts an activation score (z-score)
based on the direction of regulation (up or down) of DEGs. Diameter of circles represent the overlap between DEGs and genes annotated to the
respective pathways. c Principal component analysis of all genes expressed (CPM > 0.1) in each sample, cluster vehicle administered Brd1+/− mice
separately from vehicle WT mice, and shows that treatment with IMN or FLX normalizes amygdaloid gene expression in Brd1+/− mice. d Heatmap
showing the 144 genes surviving correction for multiple testing (FDR). DEGs are generally more abundantly expressed in vehicle administered
Brd1+/− mice than in vehicle administered WT mice, whereas IMN or FLX both completely normalizes expression of this subset of genes. e Gene
expression profile in aCC tissue from vehicle administered and IMN administered female WT (n= 8–10/group) and Brd1+/− (n= 8–10/group) mice.
Gray color marks genes that are nominally significantly differentially expressed between Brd1+/− and WT mice. f Gene expression profile in CPu tissue
from vehicle administered and IMN administered female WT (n= 8–10/group) and Brd1+/− (n= 8–10/group) mice. Gray, red, and blue color mark
genes that are nominally significantly differentially expressed, significantly upregulated after FDR correction, and significantly downregulated after
FDR correction between Brd1+/− and WT mice, respectively. g Functional genomic analysis using ingenuity pathway analysis IPA software identifies
pathways that are enriched with nominally significantly CPu DEGs and predicts an activation score (z-score) based on the direction of regulation (up
or down) of DEGs. Diameter of circles represent the overlap between DEGs and genes annotated to the respective pathways. h Principal component
analysis of all genes expressed (CPM > 0.1) in each sample, cluster vehicle administered Brd1+/− mice separately from vehicle administered WT mice
but shows that CPu treatment effect of IMN, in terms of gene expression changes, is largely on WT mice and not Brd1+/− mice.
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regions, we find that the dopamine receptor 2 (Drd2) and
dopamine transporter (Slc6a3) are among the dysregu-
lated genes in aCC and AMG, respectively (Fig. 4a, e).
Monoamines act through activation of either G protein or
ion channel linked surface receptors, which trigger second
messenger systems (e.g. 3′–5′-cyclic adenosine mono-
phosphate (cAMP), Rho family GTPases, inositol 1,4,5-
trisphosphate (IP3) or calcium (Ca2+)). They, in turn,
activate downstream kinases (e.g. protein kinase A
(PKA)), which phosphorylate the transcription factor
cAMP response element-binding protein (CREB) that
regulates expression of many immediate early and late
response genes. Convincingly, DEGs across examined
tissues particularly cluster in GPCR-controlled intracel-
lular signaling pathways and comprise immediate early
and late response genes like neurotrophic factors (e.g.
GDNF68 and NGF). Dysregulation of these signaling cas-
cades are commonly reported in affective disorders69–73,
reduced levels of phosphorylated CREB74 and neuro-
trophin receptors75 have been reported in the post-
mortem frontal cortices of people with MDD and cortical
IP3 has been suggested as a biomarker for depressive
symptoms across diagnostic boundaries76. Interestingly,
DEGs in the examined brain tissues reflect regional dif-
ferences in intracellular signaling activity. Particularly,
transcriptomic data from AMG tissue suggest increased
Gaq mediated signaling, and thus increased PI3 activity,
whereas this is the opposite in CPu tissue. CPu gene
expression was further associated with reduced signaling
mediated by Gas and Gai and their associated second
messenger (cAMP).
The antagonistic effect of antidepressants on BRD1
mediated dysregulation is tissue specific
Supporting the predictive validity of Brd1+/− mice as a
model for depressive psychopathology, administration of
either of the two tested antidepressants, IMN and FLX,
effectively alleviated the behavioral changes displayed by
Brd1+/− mice in the TST and FST without affecting basal
motor behaviors. This effect was further apparent at the
molecular level, where IMN administration essentially
normalized AMG gene expression without affecting the
expression of Brd1. This was also the case for FLX, but at
the selected dose, significant gene-regulatory changes
were additionally seen in WT mice. In aCC, IMN treat-
ment completely normalized Drd2 expression and Slc6a3,
possibly reflecting a normalization of dopamine signaling
in this tissue. Furthermore, expression of Slc25a35, which
is a marker of mitochondrial dysfunction in brain regions
under experimental mixed anxiety/depression-like dis-
order77, was additionally normalized following IMN
administration (Fig. 4e). However, as basal gene expres-
sion, measured in the vehicle administered group, did not
differ much between Brd1+/− and WT mice, the
neuromolecular effect of antidepressant treatment was
less apparent in this tissue. Surprisingly, in CPu, where
large changes in basal gene expression were observed
between WT and Brd1+/− mice, the effect IMN admin-
istration was much more pronounced in WT than in
Brd1+/− mice. Similar findings have been reported from
other rodent models with depressive-like phenotypes78,79.
Histone modification and chromatin modeling play a
role in multiple physiological and pathological processes
in the brain, including cognition80, circadian rhythms81,
and the development of affective pathology8,51. Here we
show that the schizophrenia and bipolar disorder asso-
ciated epigenetic reader, BRD1, governs affective beha-
viors and associated neuromolecular and biological
pathways in mice. In line with BRD1’s reported function
as a co-regulator of nuclear hormone receptors17,18,23 and
their targeted transcriptional response to gonadosteroid
and corticosteroid signaling17, the effect of reduced Brd1
expression is sex-biased, with only female mice displaying
changes in affective behaviors. BRD1 may thus provide an
important link between averse environmental risk factors
(.e.g. sex and stress) and depression. While equating Brd1
deficiency with depression susceptibility is over-simplistic,
female Brd1+/− mice set the stage for further studies
evaluating the epigenetic changes and neurodevelop-
mental abnormalities, pertinent to depression.
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